Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PART Pilot Study: Immunosuppression Duration After Kidney Transplant Failure
NCT06802822Not yet recruiting
- Sponsor
- University of British Columbia
- Start
- Jan 2025
- Primary completion
- Dec 2027
- Modality
- Peptides, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of tacrolimus and cyclosporine in Allosensitization (2 arms), sponsored by University of British Columbia. Primary endpoints: Clinically relevant increase in sensitization defined by a significant rise in calculated panel reactive antibody (cPRA) at 24 months, Treatment Adherence at 24 months and 2 more. Planned start Jan 2025; status: not yet recruiting.
02
Drugs
tacrolimuscyclosporine
03
Conditions
Allosensitization
Beyond the preview
Go deeper on NCT06802822.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06802822.